Eli Lilly announced that an investigational agent targeting beta-amyloid, Donanemab, appeared to slow decline in patients with early symptoms of Alzheimer’s disease. The drug showed significant slowing versus placebo on a composite measure of cognition and daily function in the phase II TRAILBLAZER-ALZ study.
The medication met the primary endpoint of change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS*), slowing decline by 32% relative to placebo. The trial enrolled 272 patients with early symptomatic Alzheimer’s disease who were selected based on cognitive assessments and imaging data.
Donanemab’s safety, tolerability, and efficacy are being evaluated in the ongoing phase II TRAILBLAZER-ALZ2 study. For more information on this study and the hope for residents living with Alzheimer’s disease please visit ClinicalTrials.gov. Stay well, mask up and stay tuned!